ProKidney (MEX:PROK) Gross-Profit-to-Asset % : 0.00% (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is ProKidney Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. ProKidney's annualized Gross Profit for the quarter that ended in Mar. 2024 was MXN0.00 Mil. ProKidney's average Total Assets over the quarter that ended in Mar. 2024 was MXN6,786.98 Mil. Therefore, ProKidney's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 0.00%.

ProKidney Gross-Profit-to-Asset % Historical Data

The historical data trend for ProKidney's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProKidney Gross-Profit-to-Asset % Chart

ProKidney Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

ProKidney Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of ProKidney's Gross-Profit-to-Asset %

For the Biotechnology subindustry, ProKidney's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ProKidney's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where ProKidney's Gross-Profit-to-Asset % falls into.

ProKidney Gross-Profit-to-Asset % Calculation

ProKidney's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (10098.85	+	7138.554)	/ 2 )
	=	0	/	8618.702
	=	0.00 %

ProKidney's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	0	/	( (7138.554	+	6435.414)	/ 2 )
	=	0	/	6786.984
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

ProKidney Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of ProKidney's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProKidney (MEX:PROK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProKidney Corp (MEX:PROK) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

PROK:USA

Address

2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103

Website

https://www.prokidney.com

ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease.